I decided to add CytoSorb. The next morning, the patient was immediately weaning off pressers, and it was a real game changer.
We treated more than 75 patients with CytoSorb® because we realized, we feel, we see, we measure a significant effect on the evolution of the patient.
In coronary patients with low ejection fraction, endocarditis, we use it almost routinely. It has been a valuable support. We have seen shorter hospital stays.